Drugs / MVA-C
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01922284 | Jun 2013 → Jan 2014 | HIV infectious disease | Imperial College London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVAC | “The second vaccine MVAC, is derived from vaccinia virus which has been modified so that it cannot divide.” NCT01922284 ↗ |
| Modality | Vaccine | “The second vaccine MVAC, is derived from vaccinia virus which has been modified so that it cannot divide.” NCT01922284 ↗ |
| Route | Intramuscular | “All immunisations will be administered by the intramuscular route (IM).” NCT01922284 ↗ |